SLC5A2 and hepatorenal syndrome: However, there were no associations between use of SGLT-2 inhibitors and incidence of variceal bleed (HR, 0.98 [95% CI, 0.82-1.19]; E-value, 1.3), hepatic encephalopathy (HR, 1.35 [95% CI, 1.00-1.83]; E-value, 1.81), hepatorenal syndrome (HR, 0.41 [95% CI, 0.15-1.15]; E-value, 1.93), spontaneous bacterial peritonitis (HR, 1.01 [95% CI, 0.51-2.01]; E-value, 1.32), or hypoglycemia (HR, 0.68 [95% CI, 0.39-1.18]; E-value, 2.85).